Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
For over fifty years lithium has been a fundamental component of therapy for patients with bipolar disorders. Lithium has been considered recently for its potential to alleviate neuronal loss and other neurodegeneration processes. For instance, lithium reduces the severity of some behavioral complications of Alzheimer's disease (AD). And there are growing indications that lithium may be of benefit to the underlying pathology of AD, as well as an array of other common CNS disorders, including stroke, Parkinson's disease, and Huntington's disease. Despite these demonstrated and prospective therapeutic benefits, lithium's mechanism of action remains elusive, and opinions differ regarding the most relevant molecular targets. Lithium inhibits several enzymes; significant among these are inositol monophosphatase (IMPase), glycogen synthase kinase-3 (GSK-3), and the proteasome. Most recent publications discussing the medical application of lithium have converged on GSK-3, so this article reviews data and discussions regarding the roles and interactions of GSK-3 with other proteins and its proposed role in the pathogenesis of Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 1×
“This somewhat unusual “sign-change” type of activation by inhibition of an inhibitor (GSK-3) is therefore a common element of GSK-3 action in both the insulin and Wnt signaling pathways [4].”
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · cited 2×
“Lithium is clearly able to inhibit directly both GSK-3 and GSK-3 [8], apparently by competing with magnesium [9].”
Phosphorylation affects the ability of tau protein to promote microtubule assembly.
Lindwall, G., & Cole, R. D. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42989-9 · Cited by 901 · cited 1×
“There are many phosphorylation sites in tau, but phosphorylation at a specific subset of these sites interferes with the ability of the protein to bind and stabilize microtubules [104].”
Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.-P., & Anderton, B. H. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90774-2 · Cited by 737 · cited 1×
“AT8 P-Ser202 / P-Thr205 [106] PHF-1 P-Ser396 / P-Ser404 [110] [113] Tau-1 u-Ser199 / u-Ser202 [110] [111] [113] Tau[pT 205 ] P-Thr205 [114] Tau[pS 396 ] P-Ser396 [114] TG3 P-Thr231 / P-Ser235 [115] The conventional names of antibodies often used to analyze Tau phosphorylation are listed, along with…”
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 2×
“In transgenic mice overexpressing mutant human tau, lithium treatment reduces axonal degeneration and the amount of hyperphosphorylated tau [16].”
Lithium-induced increase in human brain grey matter
Moore, G. J., Bebchuk, J. M., Wilds, I. B., Chen, G., & Menji, H. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02793-8 · Cited by 649 · cited 1×
“The implications of pharmacological manipulation of such events for human health is manifest in the association of lithium therapy with an increase in the volume grey matter in bipolar patients, an effect linked to the neuroprotective properties of lithium [17].”
Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459
Distribution, Levels, and Activity of Glycogen Synthase Kinase-3 in the Alzheimer Disease Brain
PEI, J.-J., TANAKA, T., TUNG, Y.-C., BRAAK, E., IQBAL, K., & GRUNDKE-IQBAL, I. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199701000-00007 · Cited by 371
Cited by
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease
Chen, Q., Du, Y., Zhang, K., Liang, Z., Li, J., Yu, H., Ren, R., Feng, J., Jin, Z., Li, F., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07625 · Cited by 280
“Glycogen synthase kinase 3β (GSK3β), a proline-directed tau kinase that phosphorylate tau at serine and threonine residues and the phosphorylated protein kinase B (Akt), a upstream kinase of GSK3β are two important kinases in the tau pathology of AD.66 The inactivation of Akt and activation of GSK-3β were found in OA…”
BackgroundInfluentialThe role of the Wnt canonical signaling in neurodegenerative diseases
Libro, R., Bramanti, P., & Mazzon, E. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.06.024 · Cited by 163
Kapfhamer, D., Berger, K. H., Hopf, F. W., Seif, T., Kharazia, V., Bonci, A., & Heberlein, U. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1292-10.2010 · Cited by 71
“In particular, glycogen synthase kinase 3 (GSK3 ) has been implicated in Parkinson’s disease, Alzheimer’s disease, and mood disorders (Koo and Kopan, 2004; O’Brien et al., 2004; Gould et al., 2006; Prickaerts et al., 2006; Aghdam and Barger, 2007; Rowe et al., 2007).”
Background
Metadata
- Authors
- Yadranji Aghdam, S., & Barger, S.
- Venue
- Current Alzheimer Research
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-02-01
- Volume
- 4
- Issue
- 1
- Pages
- 21-31
- ISSN
- 1567-2050 (ISSN-L)
- OpenAlex
- W2039873727
- Cited by
- 61
- References
- 13
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium. https://app.cochat.ai/papers/10.2174/156720507779939832
- The paper
- Yadranji Aghdam, S., & Barger, S. (2007). Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium. Current Alzheimer Research. https://doi.org/10.2174/156720507779939832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.